Companies Related to "Flexion Therapeutics FLXN Mike Clayman 2017 Results Earnings" [Most Relevant Company Matches] RSS

15:49 EST 20th November 2017 | BioPortfolio

Here are the most relevant search results for "Flexion Therapeutics FLXN Mike Clayman 2017 Results Earnings" found in our extensive corporate database of over 50,000 company records.

Showing "Flexion Therapeutics FLXN Mike Clayman 2017 Results Earnings" Companies 1–25 of 2,600+

Extremely Relevant

Flexion Therapeutics

Flexion Therapeutics in-licenses clinically enabled drug candidates with high-value specialty potential and develops these to proof of concept (PoC) and beyond. The independent company was founded in 2007 by Mike Clayman and Neil Bodick, both deeply knowledgeable drug developers, who previously created Eli Lilly’s Chorus division. Chorus became uniquely ...


Simpirica Spine Inc.

Simpirica Spine was founded in 2006 to develop minimally invasive, flexion-restricting stabilization devices for the spine. The company’s lead product, the LimiFlex Spinal Stabilization System, is designed to address flexion (forward bending) pain and instability without the need for spinal fusion. LimiFlex is CE marked and available in markets outsid...

Simpirica Spine, Inc.

Simpirica Spine, Inc. was founded in 2006 to develop minimally invasive, flexion-restricting stabilization devices for the spine. Outside the U.S., the company’s lead product, the LimiFlex Spinal Stabilization System, is CE marked and is typically used in conjunction with a surgical decompression for the treatment of lumbar spinal stenosis with ...

Tango Therapeutics

Tango Therapeutics is a biotechnology company developing novel medicines for patients by discovering and drugging context-dependent vulnerabilities in cancers. Tango was launched in 2017 by Third Rock Ventures and is headquartered in Cambridge, Mass. For more information, please visit

Maverick Therapeutics Inc.

Maverick Therapeutics is pioneering the next generation of redirected T cell therapeutics in immuno-oncology. Maverick’s highly innovative platform is designed to deliver potent activity with increased tumor specificity and reduced toxicity, resulting in superior therapeutics for cancer patients and improved clinical success. Maverick was founded by M...


PRTM has followed one principle since our founding in 1976—to make a lasting difference for our clients. The only way we can get those kinds of results is to work relentlessly and passionately as a global team with our clients.What does that mean? It means we offer insights with the power to transform the very way a company operates. We live and breathe your ecosystem, your business, your operat...


Bill founded Inverseon, recruited the Inverseon team and raised funding to support proof-of-concept clinical trials. Bill began his industrial career as a venture associate at Paramount Capital. He then worked in medical affairs at Roche Laboratories. In '00, Bill founded an independent strategic advisory practice, which was incorporated as EGB Advisors, LLC in '02. Bill is currently a Managing Di...


Affibody has developed a unique pipeline of affinity ligands in oncology, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics. The company has obtained outstanding clinical molecular imaging results and promising targeted therapeutics pre-clinical results. Affibody expects to launch one molecular imaging agent per year from 2007 and to file ...

TM3 Therapeutics

TM3 Therapeutics is focused on novel treatments for neurodegenerative and metabolic diseases by developing unique metabolite replacement therapies. Our goal is to improve survival outcomes and quality of life of patients with rare, genetic neurological diseases that have limited or no treatment options. Our clinical development program specifically targets...

Capital Earnings & Research

The Office of Dr. Mike Canales

vTv Therapeutics Inc. vTv Therapeutics Inc. vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflamma...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, is an oral histamine H4 receptor antagonist, currently in two Phase 2a studies: the first in atopic dermatitis is fully recruited and will read out in Q2 2016; and the second has ...

Ballantyne Strong, Inc. (Investor Relations section) or


Alcresta Therapeutics, Inc.

Alcresta Therapeutics, Inc. is dedicated to developing and commercializing novel enzyme-based products designed to treat gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency, which results in malabsorption common in cysti...

Inscope Medical Solutions

Inscope Medical Solutions is an innovative medical device company located in Jeffersonville, IN. Their first product, the Inscope Direct, is the first laryngoscope to integrate controllable suction to quickly remove secretions for a clear view of vocal cords allowing easy placement of the endotracheal tube. The company has won multiple awards for the Insco...

Foundation for a Smoke-Free World

WHEN: September 13, 2017, 9:30am EDT

Club Pilates

Founded in 2007, Club Pilates is a boutique fitness studio that specializes in strength-training classes for anyone, at any age. Based in Costa Mesa, CA, the company is experiencing rapid growth and expects to have nearly 350 locations open by the end of the year. With more than 500 instructors teaching over seven million workouts each year, Club Pilates i...

Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States ea...

Scientists for Wired Technology

Tizona Therapeutics, Inc.

Tizona Therapeutics, Inc., is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system’s function. In cancer, tumor cells evade recognition by c...

Azaya Therapeutics Inc.

Azaya Therapeutics, Inc. is an oncology company focused on developing more effective cancer treatments through its novel nanotechnology platform. Azaya’s patented Protein Stabilized Liposomes™ (PSL) platform allows for high-dose delivery of potent cytotoxics with potentially lower side effects. ATI-1123, is a novel liposomal encapsulation of Doce...

Probably Relevant

Blade Therapeutics

Blade Therapeutics is a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade has assembled a critical mass of fibrosis expertise and a top-tier leadership team and world-class network of advisors with unparalleled experience in anti-fibrotic drug R&D. Blade ’s lead program is a small molecule...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other advanced lung diseases. Founded in 2001, Aeris Therapeutics is privately held, with corporate offices in Woburn, MA.

More From BioPortfolio on "Flexion Therapeutics FLXN Mike Clayman 2017 Results Earnings"

Quick Search

Corporate Database Quicklinks